Can one kidney drug expand treatment to millions more patients?

This episode of the PeerDirect Medical News Podcast reviews three developments with potential implications across nephrology, oncology, and public health. Highlights include the FIND-CKD trial showing finerenone may slow disease progression in chronic kidney disease patients without diabetes, seven-year CROWN trial data demonstrating durable long-term disease control with lorlatinib in advanced ALK-positive lung cancer, and a JAMA Network Open study linking measles-related vitamin A misinformation to increased toxic exposures. Together, these findings underscore evolving treatment paradigms and the growing impact of health communication on patient outcomes.